Acquired initiating mutations in early hematopoietic cells of CLL patients

Cancer Discov. 2014 Sep;4(9):1088-101. doi: 10.1158/2159-8290.CD-14-0104. Epub 2014 Jun 11.

Abstract

Appropriate cancer care requires a thorough understanding of the natural history of the disease, including the cell of origin, the pattern of clonal evolution, and the functional consequences of the mutations. Using deep sequencing of flow-sorted cell populations from patients with chronic lymphocytic leukemia (CLL), we established the presence of acquired mutations in multipotent hematopoietic progenitors. Mutations affected known lymphoid oncogenes, including BRAF, NOTCH1, and SF3B1. NFKBIE and EGR2 mutations were observed at unexpectedly high frequencies, 10.7% and 8.3% of 168 advanced-stage patients, respectively. EGR2 mutations were associated with a shorter time to treatment and poor overall survival. Analyses of BRAF and EGR2 mutations suggest that they result in deregulation of B-cell receptor (BCR) intracellular signaling. Our data propose disruption of hematopoietic and early B-cell differentiation through the deregulation of pre-BCR signaling as a phenotypic outcome of CLL mutations and show that CLL develops from a pre-leukemic phase.

Significance: The origin and pathogenic mechanisms of CLL are not fully understood. The current work indicates that CLL develops from pre-leukemic multipotent hematopoietic progenitors carrying somatic mutations. It advocates for abnormalities in early B-cell differentiation as a phenotypic convergence of the diverse acquired mutations observed in CLL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cluster Analysis
  • Gene Expression Profiling
  • Hematopoietic Stem Cells / metabolism*
  • Hematopoietic Stem Cells / pathology*
  • Humans
  • Immunoglobulin Heavy Chains / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Multipotent Stem Cells / metabolism
  • Multipotent Stem Cells / pathology
  • Mutation*
  • Phosphoproteins / genetics
  • RNA Splicing Factors
  • Receptors, Antigen, B-Cell / metabolism
  • Ribonucleoprotein, U2 Small Nuclear / genetics
  • Signal Transduction

Substances

  • Immunoglobulin Heavy Chains
  • Phosphoproteins
  • RNA Splicing Factors
  • Receptors, Antigen, B-Cell
  • Ribonucleoprotein, U2 Small Nuclear
  • SF3B1 protein, human